Developer docs
API playgroundTry for free, no card

Search company profiles

IBSA PHARMA INC

Full company profile

uuid02l5cag

Namestring
IBSA PHARMA INC
Legal namestring
IBSA Pharma Inc.
Websiteurl
ibsapharma.com
Company typeenum
Private
Founded yearint
1945
Descriptiontext

IBSA Pharma Inc. is the US commercial subsidiary of IBSA Group (Institut Biochimique SA), a Swiss multinational pharmaceutical company founded in 1945 in Lugano, Switzerland. The company develops and commercializes pharmaceutical products across 10 therapeutic areas, with its US operations focused on Endocrinology, Pain and Inflammation, and Urology. Its portfolio is differentiated by two proprietary drug delivery technology platforms: FilmTec, an advanced pharmaceutical formulation technology, and Topical Patch Technology, a targeted, patient-centered delivery system for pain and inflammatory conditions. The company maintains a registered FilmTec trademark and operates under a four-pillar framework (Person, Innovation, Quality, Responsibility) aligned with ESG goals.

The US subsidiary is headquartered in Parsippany, New Jersey, and sells through established pharmaceutical distribution channels as well as the proprietary IBSA Direct program. The parent group reaches 90 countries across 5 continents through 20 wholly-owned subsidiaries in Europe, China, and the United States, employing 2,500+ people worldwide. Its go-to-market is sales-led, relying on prescription and medical channels rather than disclosed direct-to-consumer or platform models, and pricing is not publicly disclosed. Customer segments are defined by therapeutic use case (endocrine, pain/inflammation, urology patients) rather than enterprise logos.

Revenue is generated through one-time sales of prescription pharmaceutical products across multiple therapeutic areas. The company's value proposition centers on advanced drug delivery technologies enabling targeted, patient-centered solutions, supported by an 80+ year heritage, a global subsidiary network, and an associated IBSA Foundation that funds scientific research and fellowships. No public listing, funding rounds, M&A activity, or leadership changes are disclosed in the available sources.

Short descriptiontext

IBSA Pharma Inc. is the US subsidiary of Swiss multinational IBSA Group, commercializing prescription pharmaceuticals in endocrinology, pain and inflammation, and urology via proprietary FilmTec and topical patch drug delivery technologies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersParsippany, United States
HQ citystring
Parsippany
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical products, endocrine treatments, pain management drugs, urology therapeutics, topical drug delivery
Industry1 code
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Products
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

IBSA Pharma Inc. generates revenue through the sale of pharmaceutical products across multiple therapeutic areas including endocrinology, pain and inflammation, and urology. Products are distributed through subsidiaries and partners in 90 countries across 5 continents.

ibsausa.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

IBSA Pharma Inc. is the US subsidiary of Swiss multinational IBSA Group (Institut Biochimique SA), founded in 1945. The company develops, manufactures, and commercializes pharmaceutical products across 10 therapeutic areas, with US market focus on Endocrinology, Pain and Inflammation, and Urology. It leverages proprietary drug delivery platforms including FilmTec® technology and topical patch systems to deliver targeted, patient-centered therapies distributed through its global subsidiary network and the IBSA Direct access program.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

IBSA Pharma Inc. is a Swiss multinational pharmaceutical company offering a portfolio of products across 10 therapeutic areas. The company focuses on Endocrinology, Pain and Inflammation, and Urology in the US market. IBSA develops proprietary drug delivery technologies including FilmTec® Technology and Topical Patch Technology. Products are distributed through the IBSA Direct program and reach over 90 countries globally through 20 subsidiaries.

Product and service1 record
1Endocrinology Products
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOthers
Description

IBSA Foundation is a separate organization that supports scientific research through fellowships and awards. The foundation honors researchers and promotes innovation in science and medicine, contributing to IBSA's reputation and talent network.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Spanish-listed specialty pharma with strong dermatology and pain portfolios and European commercial roots. Comparable in mid-size specialty positioning and therapeutic breadth.

TypeDirect peer
Description

Italian specialty pharma operating across endocrinology, urology, and pain with established global subsidiaries. Comparable in therapeutic categories, mid-cap scale, and European heritage with US operations.

TypeDirect peer
Description

Hungarian specialty pharma with branded women's health, endocrinology, and CNS franchises. Comparable in mid-cap scale, branded specialty positioning, and direct European-to-US commercialization pathway.

TypeDirect peer
Description

Belgian specialty pharma focused on neurology, immunology, and rare diseases. Comparable in mid-cap branded specialty positioning and global subsidiary distribution.

TypeDirect peer
Description

Danish specialty pharma with a focused branded portfolio and global direct-to-market presence. Comparable in mid-cap scale, specialty/branded positioning, and multi-country subsidiary distribution model.

TypeDirect peer
Description

Privately-held Swiss-headquartered specialty pharma with overlapping therapeutic focus in reproductive medicine, urology, and endocrinology. Closely comparable in structure (private, mid-size, Swiss heritage), therapeutic portfolio, and global subsidiary model.

TypeDirect peer
Description

Private, family-owned European specialty pharma with a multi-therapeutic-area portfolio and direct presence in the US. Comparable in ownership structure (private group, wholly-owned subsidiaries), breadth of therapeutic areas, and mid-size global footprint.

TypeDirect peer
Description

German specialty and generics group with broad European footprint and growing branded specialty portfolio. Comparable in multi-country subsidiary model and European private-equity-backed ownership structure.

TypeBroad incumbent
Description

German science and technology group with a Healthcare division overlapping in fertility, endocrinology, and specialty pharma. Comparable in therapeutic areas and Swiss-quality-adjacent heritage, but materially larger and publicly listed.

TypeDirect peer
Description

French-listed specialty pharma with a focused multi-therapeutic portfolio including urology and pain. Comparable in mid-size specialty positioning, therapeutic area focus, and global commercial footprint.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries19 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

IBSA PHARMA INC

Pharmaceutical Productsibsapharma.com

IBSA Pharma Inc. is the US subsidiary of Swiss multinational IBSA Group, commercializing prescription pharmaceuticals in endocrinology, pain and inflammation, and urology via proprietary FilmTec and topical patch drug delivery technologies.

What IBSA PHARMA INC does

IBSA Pharma Inc. is the US commercial subsidiary of IBSA Group (Institut Biochimique SA), a Swiss multinational pharmaceutical company founded in 1945 in Lugano, Switzerland. The company develops and commercializes pharmaceutical products across 10 therapeutic areas, with its US operations focused on Endocrinology, Pain and Inflammation, and Urology. Its portfolio is differentiated by two proprietary drug delivery technology platforms: FilmTec, an advanced pharmaceutical formulation technology, and Topical Patch Technology, a targeted, patient-centered delivery system for pain and inflammatory conditions. The company maintains a registered FilmTec trademark and operates under a four-pillar framework (Person, Innovation, Quality, Responsibility) aligned with ESG goals.

The US subsidiary is headquartered in Parsippany, New Jersey, and sells through established pharmaceutical distribution channels as well as the proprietary IBSA Direct program. The parent group reaches 90 countries across 5 continents through 20 wholly-owned subsidiaries in Europe, China, and the United States, employing 2,500+ people worldwide. Its go-to-market is sales-led, relying on prescription and medical channels rather than disclosed direct-to-consumer or platform models, and pricing is not publicly disclosed. Customer segments are defined by therapeutic use case (endocrine, pain/inflammation, urology patients) rather than enterprise logos.

Revenue is generated through one-time sales of prescription pharmaceutical products across multiple therapeutic areas. The company's value proposition centers on advanced drug delivery technologies enabling targeted, patient-centered solutions, supported by an 80+ year heritage, a global subsidiary network, and an associated IBSA Foundation that funds scientific research and fellowships. No public listing, funding rounds, M&A activity, or leadership changes are disclosed in the available sources.

IBSA PHARMA INC firmographics

Firmographics
Name
IBSA PHARMA INC
Legal name
IBSA Pharma Inc.
Website
https://ibsapharma.com
Company type
Private
Founded year
1945
Operating status
Operating
Headcount range
101–250 employees
Short description
IBSA Pharma Inc. is the US subsidiary of Swiss multinational IBSA Group, commercializing prescription pharmaceuticals in endocrinology, pain and inflammation, and urology via proprietary FilmTec and topical patch drug delivery technologies.
Ownership category
akta.pro rank

IBSA PHARMA INC industry classification

Industry
Product category
Pharmaceutical Products
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Pharmaceutical products
  • Endocrine treatments
  • Pain management drugs
  • Urology therapeutics
  • Topical drug delivery

Where IBSA PHARMA INC is headquartered

Location

Headquarters

HQ city
Parsippany
HQ country
United States
HQ region
North America

Offices1 record

Markets served

IBSA PHARMA INC business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. Pharmaceutical Product Sales: IBSA Pharma Inc. generates revenue through the sale of pharmaceutical products across multiple therapeutic areas including endocrinology, pain and inflammation, and urology. Products are distributed through subsidiaries and partners in 90 countries across 5 continents.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

IBSA PHARMA INC product offering

Product offering

Core offering

IBSA Pharma Inc. is the US subsidiary of Swiss multinational IBSA Group (Institut Biochimique SA), founded in 1945. The company develops, manufactures, and commercializes pharmaceutical products across 10 therapeutic areas, with US market focus on Endocrinology, Pain and Inflammation, and Urology. It leverages proprietary drug delivery platforms including FilmTec® technology and topical patch systems to deliver targeted, patient-centered therapies distributed through its global subsidiary network and the IBSA Direct access program.

Product overview

IBSA Pharma Inc. is a Swiss multinational pharmaceutical company offering a portfolio of products across 10 therapeutic areas. The company focuses on Endocrinology, Pain and Inflammation, and Urology in the US market. IBSA develops proprietary drug delivery technologies including FilmTec® Technology and Topical Patch Technology. Products are distributed through the IBSA Direct program and reach over 90 countries globally through 20 subsidiaries.

Differentiator

Problem solved

Functional benefit

Products and services

  • Endocrinology Products

Companies that use IBSA PHARMA INC

Customer profile

Segments3 records

Ideal customer profiles1 record

IBSA PHARMA INC technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

IBSA PHARMA INC partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • IBSA FoundationcoreOthersIBSA Foundation is a separate organization that supports scientific research through fellowships and awards. The foundation honors researchers and promotes innovation in science and medicine, contributing to IBSA's reputation and talent network.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

IBSA PHARMA INC competitors and assessment

Company assessment

Direct peers

  • Almirall: Spanish-listed specialty pharma with strong dermatology and pain portfolios and European commercial roots. Comparable in mid-size specialty positioning and therapeutic breadth.
  • Recordati: Italian specialty pharma operating across endocrinology, urology, and pain with established global subsidiaries. Comparable in therapeutic categories, mid-cap scale, and European heritage with US operations.
  • Gedeon Richter: Hungarian specialty pharma with branded women's health, endocrinology, and CNS franchises. Comparable in mid-cap scale, branded specialty positioning, and direct European-to-US commercialization pathway.
  • UCB: Belgian specialty pharma focused on neurology, immunology, and rare diseases. Comparable in mid-cap branded specialty positioning and global subsidiary distribution.
  • Lundbeck: Danish specialty pharma with a focused branded portfolio and global direct-to-market presence. Comparable in mid-cap scale, specialty/branded positioning, and multi-country subsidiary distribution model.
  • Ferring Pharmaceuticals: Privately-held Swiss-headquartered specialty pharma with overlapping therapeutic focus in reproductive medicine, urology, and endocrinology. Closely comparable in structure (private, mid-size, Swiss heritage), therapeutic portfolio, and global subsidiary model.
  • Chiesi Farmaceutici: Private, family-owned European specialty pharma with a multi-therapeutic-area portfolio and direct presence in the US. Comparable in ownership structure (private group, wholly-owned subsidiaries), breadth of therapeutic areas, and mid-size global footprint.
  • STADA Arzneimittel: German specialty and generics group with broad European footprint and growing branded specialty portfolio. Comparable in multi-country subsidiary model and European private-equity-backed ownership structure.
  • Ipsen: French-listed specialty pharma with a focused multi-therapeutic portfolio including urology and pain. Comparable in mid-size specialty positioning, therapeutic area focus, and global commercial footprint.

Broad incumbents

  • Merck KGaA (Healthcare): German science and technology group with a Healthcare division overlapping in fertility, endocrinology, and specialty pharma. Comparable in therapeutic areas and Swiss-quality-adjacent heritage, but materially larger and publicly listed.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

IBSA PHARMA INC social profiles

Digital presence

IBSA PHARMA INC financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IBSA PHARMA INC leadership team

Management profile

Number of profiles

IBSA PHARMA INC subsidiaries and ownership

Company hierarchy

Subsidiaries19 records

IBSA PHARMA INC funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IBSA PHARMA INC M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IBSA PHARMA INC

What does IBSA PHARMA INC do?

IBSA Pharma Inc. is the US subsidiary of Swiss multinational IBSA Group (Institut Biochimique SA), founded in 1945. The company develops, manufactures, and commercializes pharmaceutical products across 10 therapeutic areas, with US market focus on Endocrinology, Pain and Inflammation, and Urology. It leverages proprietary drug delivery platforms including FilmTec® technology and topical patch systems to deliver targeted, patient-centered therapies distributed through its global subsidiary network and the IBSA Direct access program.

Is IBSA PHARMA INC a public or private company?

IBSA PHARMA INC is a private company. It is classified as corporate owned and is currently operating.

When was IBSA PHARMA INC founded?

IBSA PHARMA INC was founded in 1945. It employs 101 to 250 people.

Where is IBSA PHARMA INC based?

IBSA PHARMA INC is headquartered in Parsippany, United States, in the North America region.

How does IBSA PHARMA INC make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are IBSA PHARMA INC's main competitors?

Direct peers on record are Almirall, Recordati, Gedeon Richter, UCB, Lundbeck, Ferring Pharmaceuticals, Chiesi Farmaceutici, STADA Arzneimittel and Ipsen. Merck KGaA (Healthcare) is listed as a broad incumbent.

Does IBSA PHARMA INC have an API?

No public API is recorded for IBSA PHARMA INC.

What industry is IBSA PHARMA INC in?

IBSA PHARMA INC's product category is Pharmaceutical Products. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceIBSA Pharma and Mark Cuban Cost Plus Drug Company Team Up to Make Tirosint More AffordableIBSA Pharma announced an agreement with Mark Cuban Cost Plus Drug Company to offer Tirosint oral capsules at a low cash price via the online pharmacy. This is the first branded levothyroxine drug in the program, which typically offers generics. The deal marks Cost Plus Drugs' first foray into the branded segment.PR NewswireIBSA Increases Dosage Flexibility of Liquid Hypothyroidism Treatment for Patients and Clinicians; Introduces Unique New Dosing OptionsIBSA Pharma Inc. announced the launch of three new dosage strengths (37.5, 44, and 62.5 micrograms) of its Tirosint-SOL levothyroxine oral solution for treating hypothyroidism in the United States. These new doses represent the first such options available in the U.S. market, expanding Tirosint-SOL's portfolio to 15 total dosage strengths—the widest range of any FDA-approved levothyroxine therapy. The company also enhanced its copay coupon program to improve patient access to the medication.PR NewswireNew Study Confirms That Novel Liquid Levothyroxine Solution Can be Administered as Early as 15 Minutes Before BreakfastA new study presented at the American Association of Clinical Endocrinology Annual Meeting found that IBSA Pharma Inc.'s liquid levothyroxine formulation, Tirosint-SOL, can be administered 15 minutes before breakfast without significantly affecting drug absorption or systemic availability, compared to the current FDA-mandated 30-60 minute wait time. The phase 1 bioavailability study tested 600 mcg doses in healthy volunteers fed an FDA-defined high-fat breakfast, with results showing similar drug exposure at both 15-minute and 30-minute pre-meal intervals. IBSA Institut Biochimique SA, the study sponsor, anticipates seeking FDA approval for a label change based on these findings, which researchers say could improve patient adherence to levothyroxine therapy.PR NewswireIBSA Reacquires Commercial Rights to the Flector® Brand in the USIBSA Pharma Inc. has reacquired marketing and distribution rights for Flector (diclofenac epolamine) topical system 1.3% from Pfizer, effective January 1, 2021, regaining commercial control over a product it originally developed. The company is now marketing both Flector and Licart as its two prescription topical NSAIDs for acute pain, with IBSA lowering Flector's price and introducing patient savings programs to improve accessibility. IBSA Pharma is a subsidiary of Switzerland-based IBSA Institut Biochimique SA, which operates in over 80 countries across five continents.PR NewswireLicart™ Now Available to Treat Acute Pain Due to Minor Strains, Sprains, and ContusionsIBSA Pharma Inc. announced the launch of Licart (diclofenac epolamine) topical system 1.3% in the US market for the treatment of acute pain due to minor strains, sprains, and contusions. Licart is the first and only FDA-approved once-a-day topical NSAID therapy, utilizing patented next-generation patch technology that provides pain relief within 1-3 hours and sustains it for 24 hours. The product is manufactured by IBSA Pharma, a fully-owned subsidiary of Switzerland-based IBSA Institut Biochimique SA, which positions this launch as an expansion of the company's topical pain therapy portfolio in the United States.PR NewswireTirosint®-SOL Now Available to Treat Hypothyroidism in the U.S.IBSA Pharma Inc. announced that Tirosint-SOL (levothyroxine sodium) oral solution is now available in the U.S. market for the treatment of hypothyroidism and pituitary thyrotropin suppression. The product is the first and only FDA-approved liquid levothyroxine formulation, offered in 12 different dosage strengths in monodose ampules without common excipients such as dyes, gluten, lactose, alcohol, or sugar. The medication will be available through participating retail and mail order pharmacies starting March 1st, with various patient assistance programs including copay savings cards and direct pricing options.PR NewswireIBSA Pharma Inc. to debut at 88th Annual Meeting of the American Thyroid AssociationIBSA Pharma Inc., the U.S. subsidiary of Switzerland-based IBSA Group, will attend its first scientific meeting in the United States at the 88th Annual Meeting of the American Thyroid Association in Washington, D.C. The company announced plans to become the sole distributor and promoter of the Tirosint franchise and will launch its own detailing sales force in the coming weeks to increase commercial and clinical support for the levothyroxine product. IBSA Group, the largest privately owned pharmaceutical company in Switzerland, is expanding its presence into the U.S. market with a focus on endocrinology.PR NewswireIBSA Group establece operaciones comerciales en los EE. UU.IBSA Group, the largest privately owned pharmaceutical company in Switzerland, has established commercial operations in the United States as IBSA Pharma Inc., planning to directly distribute Tirosint® (levothyroxine sodium), an FDA-approved treatment for hypothyroidism. The company previously licensed the product to another US pharmaceutical firm and now aims to maximize the commercial value of the Tirosint franchise while introducing additional IBSA products, some still awaiting FDA approval. IBSA Pharma will deploy its own sales team in the coming months to increase commercial and clinical support for the product.